Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the DNA Repair Drugs Market?

Over the past few years, there has been a substantial expansion in the market size of DNA repair drugs. It is anticipated to rise from $10.78 billion in 2024 to $13 billion in 2025, reflecting a compound annual growth rate (CAGR) of 20.6%. The burgeoning growth during the historical period can be credited to the advancements in comprehending DNA repair processes, increased research in cancer, evolving regulations in the pharmaceutical sector, a higher incidence of genetic disorders and the growth of personalized medicine.

The market size of DNA repair drugs is anticipated to experience significant growth in the upcoming years, expanding to $26.77 billion by 2029 with a compound annual growth rate (CAGR) of 19.8%. The expected growth over the forecast period can be linked to the advancement of DNA repair-targeted therapies, the increasing emphasis on precision medicine, an aging population, and enhanced funding to foster the development of DNA repair drugs. Major trends expected during this forecast period include the utilization of artificial intelligence in DNA repair drug discovery, the formulation of mixture therapies aimed at DNA repair pathways, a focus on gene editing technologies, customized treatment plans based on DNA repair profiles, and an uptick in clinical trials centered around DNA repair drugs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12200&type=smp

Which Factor Is Shaping The Future Of The DNA Repair Drugs Market?

The increasing incidence of cancer is predicted to fuel the expansion of the DNA repair drug market. An assortment of diseases that can develop in virtually any organ or tissue, cancer occurs when abnormal cells multiply out of control, breach their normal confines and either metastasize to other organs or intrude upon nearby body parts. The uptick in the incidence of cancer is primarily spurred by factors such as smoking, radiation, obesity, cancer-inducing substances (carcinogens), and genetic mutations. By disrupting DNA’s self-repair mechanisms, cancer can be prevented as this process halts the growth and results in the death of cancerous cells. For example, data from the Australian Institute of Health and Welfare, a government entity based in Australia, show a significant yearly increase in diagnosed cancer cases in Australia from 160,570 in 2022 to 164,694 in 2023. This rising trend underscores the escalating incidence of cancer in the country. Hence, the growing prevalence of cancer is catalyzing the expansion of the DNA repair drug market.

What Is The Segment-Wise Breakdown Of The DNA Repair Drugs Market?

The dna repair drugs market covered in this report is segmented –

1) By Drug Type: Olaparib, Rucaparib, Niraparib, Talazoparib, Other Drugs

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

3) By Application: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Other Applications

Subsegments:

1) By Olaparib: Tablets, Capsules, Combination Therapies

2) By Rucaparib: Tablets, Monotherapy, Combination with Other Cancer Treatments

3) By Niraparib: Capsules, Extended-Release Formulations, Maintenance Therapy Applications

4) By Talazoparib: Capsules, Combination with Immunotherapy, High-Dose and Low-Dose Options

5) By Other Drugs: Experimental PARP Inhibitors, Generic and Biosimilar Versions, Next-Generation DNA Damage Response (DDR) Inhibitors

Which Trends Are Redefining The Future Landscape Of The DNA Repair Drugs Industry?

Emphasis on product innovation is a growing trend observed in the DNA repair drug industry. Major market players are focusing on the creation of novel products to maintain their market standing. As an example, AstraZeneca PLC, a biopharmaceutical firm based in the UK, obtained approval for Lynparza coupled with abiraterone in the United States in June 2023. This was to address BRCA-mutated metastatic castration-resistant prostate cancer. Lynparza (olaparib) stands out as the premier PARP inhibitor and is the initial targeted drug developed to inhibit the DNA damage response (DDR) in cells or tumors that do not respond to HRR (homologous recombination repair).

Which Companies Hold The Largest Market Share In The DNA Repair Drugs Sector?

Major companies operating in the DNA repair drugs market include Pfizer Inc., Johnson & Johnson Private Limited, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Biogen Inc., Ono Pharmaceutical Co. Ltd., Jiangsu HengRui Medicine Co. Ltd., BioMarin Pharmaceutical Inc., Genentech Inc., ClovisOncology Inc., Karyopharm Therapeutics Inc., Repare Therapeutics Inc., Intellia Therapeutics Inc., C4 Therapeutics Inc., Precision BioSciences, Artios Pharma Limited, FoRx Therapeutics AG, Onxeo SA, CRISPR Therapeutics AG

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/dna-repair-drugs-global-market-report

How Does Regional Performance Compare Across The DNA Repair Drugs Industry?

North America was the largest region in the DNA repair drugs market in 2024, and is expected to be the fastest-growing region in the forecast period. The regions covered in the DNA repair drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12200&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model